

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Urea derivatives selected from the group consisting of
 N-methyl-4-{4-[3-(fluorotrifluoromethylphenyl)ureido]phenoxy}-
pyridine-2-carboxamide,
 1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]-3-(2-fluoro-5-trifluoro-
methylphenyl)urea,
 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(pyridin-4-ylsulfanyl)phenyl]-
urea,
 1-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yloxy)phenyl]-3-(2-fluoro-5-
trifluoromethylphenyl)urea,
 7-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]phenoxy}benzofuran-
2-carboxamide,
 1-[4-(benzo[1,3]dioxol-5-yloxy)phenyl]-3-(2-fluoro-5-trifluoromethyl-
phenyl)urea,
 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(6-methoxypyridin-3-yloxy)-
phenyl]urea,
 methyl (5-{4-[3-(4-fluoro-3-trifluoromethylphenyl)ureido]phenoxy}-1*H*-
benzimidazol-2-yl)carbamate,
 1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]-3-(4-chloro-3-trifluoro-
methylphenyl)urea,
 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(imidazo[1,2-*a*]pyridin-8-yl-
oxy)phenyl]urea,
 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(2-methylbenzothiazol-5-yl-
oxy)phenyl]urea,
 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(1*H*-indol-6-yloxy)phenyl]-
urea,
 1-(4-chloro-3-trifluoromethylphenyl)-3-[4-(imidazo[1,2-*a*]quinolin-9-yl-
oxy)phenyl]urea,
 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(imidazo[1,2-*a*]quinolin-9-yl-

oxy)phenyl]urea,

1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(1*H*-indol-5-yloxy)phenyl]-
urea,

methyl 7-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]phenoxy}-
benzofuran-2-carboxylate,

1-[4-(benzo[1,3]dioxol-5-yloxy)phenyl]-3-(4-chloro-3-trifluoromethyl-
phenyl)urea,

1-[4-(benzo-1,2,5-thiadiazol-4-yloxy)phenyl]-3-(2-fluoro-5-trifluoro-
methylphenyl)urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[4-(6-methoxypyridin-3-yloxy)-
phenyl]urea,

1-[4-(imidazo[1,2-*a*]quinolin-9-yloxy)phenyl]-3-(4-trifluoromethoxy-
phenyl)urea,

1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)-3-methylphenyl]-3-(2-fluoro-5-
trifluoromethylphenyl)urea,

1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)-3-methylphenyl]-3-(4-chloro-3-
trifluoromethylphenyl)urea,

1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)-2-methylphenyl]-3-(2-fluoro-5-
trifluoromethylphenyl)urea,

1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)-2-methylphenyl]-3-(4-chloro-3-
trifluoromethylphenyl)urea,

1-[4-(benzo-1,2,5-thiadiazol-5-yloxy)-3-fluorophenyl]-3-(2-fluoro-5-
trifluoromethylphenyl)urea,

1-[4-(2-aminobenzothiadiazol-6-yloxy)phenyl]-3-(2-fluoro-5-trifluoro-
methylphenyl)urea,

1-[4-(2-amino-4,7-dimethylbenzothiadiazol-6-yloxy)phenyl]-3-(2-fluoro-
5-trifluoromethylphenyl)urea,

N-methyl-4-{4-[3-(2-fluoro-4-trifluoromethylphenyl)ureido]phenyl-
sulfanyl}pyridine-2-carboxamide,

and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Medicament comprising at least one compound according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and adjuvants.
3. (Original) Use of compounds according to Claim 1
and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.
4. (Original) Use according to Claim 3, where the kinases are selected from the group consisting of tyrosine kinases and/or Raf kinases.
5. (Original) Use according to Claim 1, where the tyrosine kinases are TIE-2.
6. (Currently Amended) Use according to ~~Claim 4~~ of compounds according to Claim 1, and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
for the preparation of a medicament for the treatment of diseases, which are influenced by inhibition of tyrosine kinases by the compounds of the formula I.
7. (Currently Amended) Use ~~according to Claim 6~~ for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of TIE-2 by the compounds according Claim 1.

8. (Currently Amended) Use according to Claim 6 ~~or~~ 7, where the disease to be treated is a solid tumour.
9. (Original) Use according to Claim 8, where the solid tumour originates from the group brain tumour, tumour of the urogenital tract, tumour of the lymphatic system, stomach tumour, laryngeal tumour and lung tumour.
10. (Original) Use according to Claim 8, where the solid tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.
11. (Currently Amended) Use according to Claim 6 ~~or~~ 7 for the treatment of a disease in which angiogenesis is implicated.
12. (Original) Use according to Claim 11, where the disease is an ocular disease.
13. (Currently Amended) Use according to Claim 6 ~~or~~ 7 for the treatment of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and/or inflammatory diseases.
14. (Original) Use according to Claim 13, where the inflammatory disease originates from the group rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.
15. (Currently Amended) Use according to Claim 6 ~~or~~ 7 for the treatment of bone pathologies, where the bone pathology originates from the group osteosarcoma, osteoarthritis and rickets.
16. (Original) Medicament comprising at least one compound according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further

medicament active ingredient.

17. (Original) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of a further medicament active ingredient.
18. (Original) Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound according to Claim 1 is administered in combination with a compound from the group 1) an oestrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.
19. (Original) Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound according to Claim 1 is administered in combination with radiotherapy and a compound from the group 1) an oestrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

20. (Currently Amended) Use ~~according to Claim 3, 4 or 5~~, for the preparation of a medicament for the treatment of diseases which are based on disturbed TIE-2 activity,
where a therapeutically effective amount of a compound according to Claim 1 is administered in combination with a growth-factor receptor inhibitor.
21. (Currently Amended) Use ~~according to Claim 3 or 4~~ of compounds according to Claim 1, and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
for the preparation of a medicament for the treatment of diseases which are caused, mediated and/or propagated by Raf kinases.
22. (Original) Use according to Claim 21, where the Raf kinase is selected from the group consisting of A-Raf, B-Raf and Raf-1.
23. (Original) Use according to Claim 21, where the diseases are selected from the group consisting of hyperproliferative and non-hyperproliferative diseases.
24. (Currently Amended) Use according to Claim 21 ~~or 23~~, where the disease is cancerous.
25. (Currently Amended) Use according to Claim 21 ~~or 23~~, where the disease is non-cancerous.
26. (Currently Amended) Use according to Claim 21, ~~23 or 25~~, where the non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

27. (Currently Amended) Use according to ~~one of Claims 21, 23 and 24~~ Claim 21, where the diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.